Inhibition of Bruton tyrosine kinase in patients with severe COVID-19
Abstract
Acalabrutinib targets activated BTK in macrophages and was associated with reduced inflammation and clinical improvement in COVID-19.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 26, 2020
- Source ID
- 10.1126/sciimmunol.abd0110
Entities
People
- Ahmed Hamdy
- Andre Goy
- George W Wright
- Jacob F Collen
- Jeff P. Sharman
- Jigar Desai
- Josep Baselga
- Joseph Roswarski
- Keith M. Rose
- Kevin K Chung
- Louis M Staudt
- M. Andrew Monticelli
- Marissa A. Zarakas
- Mark Roschewski
- Michael Roshon
- Michail S. Lionakis
- Raquel Izumi
- Stephen H Wrzesinski
- Wyndham H. Wilson
Organizations
- Acerta Pharma
- AstraZeneca
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- McKesson Corporation
- National Cancer Institute
- National Institute of Allergy and Infectious Diseases
- St Peter's Hospital
- Uniformed Services University of the Health Sciences
- Walter Reed National Military Medical Center
- Welsh, Carson, Anderson & Stowe